BACKGROUND AND OBJECTIVES: Currently evidence about clinical and demographic predictors of response to newer antidepressants such as duloxetine is limited. This study aimed to investigate whether a number of predictors, particularly co-morbid anxiety disorders and anxious depression, are associated with clinical improvement. METHODS: One hundred and one outpatients suffering from major depression (MD) were treated with duloxetine and assessed at baseline and at weeks 2, 4 and 8 on the 21-item Hamilton Depression Rating Scale (HDRS) and at weeks 4 and 8 on the Clinical Global Impression-Severity (CGI-S) scale. RESULTS: Patients with co-morbid panic disorder or obsessive-compulsive disorder showed slowed improvements at 2 and 4 weeks compared with patients without such co-morbidities; however, they showed slightly higher or similar improvements, respectively, at 8 weeks. Also, anxious MD patients showed higher improvements compared with non-anxious MD patients at all time points, with the difference between groups increasing over time. Several other predictors, such as co-morbid premenstrual dysphoric disorder and lifetime generalized anxiety disorder, were also identified. CONCLUSION: Our results suggest that co-morbidity with an anxiety disorder could negatively influence improvement following duloxetine treatment in the short term but that such a difference could be reversed by 8 weeks. However, given that the study had several limitations, including the lack of a comparison group and a flexible dosage design, further research is needed to replicate and extend these findings.
Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study / Nasso E.D.; Chiesa A.; Serretti A.; De Ronchi D.; Mencacci C.. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - STAMPA. - 31:(2011), pp. 385-405. [10.2165/11588800-000000000-00000]
Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.
SERRETTI, ALESSANDRO;DE RONCHI, DIANA;
2011
Abstract
BACKGROUND AND OBJECTIVES: Currently evidence about clinical and demographic predictors of response to newer antidepressants such as duloxetine is limited. This study aimed to investigate whether a number of predictors, particularly co-morbid anxiety disorders and anxious depression, are associated with clinical improvement. METHODS: One hundred and one outpatients suffering from major depression (MD) were treated with duloxetine and assessed at baseline and at weeks 2, 4 and 8 on the 21-item Hamilton Depression Rating Scale (HDRS) and at weeks 4 and 8 on the Clinical Global Impression-Severity (CGI-S) scale. RESULTS: Patients with co-morbid panic disorder or obsessive-compulsive disorder showed slowed improvements at 2 and 4 weeks compared with patients without such co-morbidities; however, they showed slightly higher or similar improvements, respectively, at 8 weeks. Also, anxious MD patients showed higher improvements compared with non-anxious MD patients at all time points, with the difference between groups increasing over time. Several other predictors, such as co-morbid premenstrual dysphoric disorder and lifetime generalized anxiety disorder, were also identified. CONCLUSION: Our results suggest that co-morbidity with an anxiety disorder could negatively influence improvement following duloxetine treatment in the short term but that such a difference could be reversed by 8 weeks. However, given that the study had several limitations, including the lack of a comparison group and a flexible dosage design, further research is needed to replicate and extend these findings.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.